Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Myasthenia Gravis ll: Pathophysiology

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...

Myasthenia Gravis: Overview and Treatment

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...

Myasthenia Gravis: Diagnostic Tests

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

Chemical Synapses

Chemical Synapses

Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...

Chemical Synapses

Chemical Synapses

Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Patterns of treatment failure and survival outcomes following definitive intensity-modulated radiotherapy in locally advanced head and neck squamous cell carcinoma: a single centre experience.

Ecancermedicalscience·2026

Same author

Neurosurgical Biopsy and Resection for Diagnosis and Treatment of Balamuthia mandrillaris Amebic Encephalitis, United States.

Emerging infectious diseases·2026

Same author

Relative frequencies of muscle specific kinase antibody myasthenia in 46 centres worldwide.

Brain : a journal of neurology·2026

Same author

From gene to function: GABA receptor-associated protein (GABARAP) interacts with and potentiates the GABA receptor (RDL) in Megalurothrips usitatus (Bagnall) (Thysanoptera: Thripidae).

Pesticide biochemistry and physiology·2026

Same author

Neuroimaging and Neuropathologic Findings in Pediatric Patients with ECMO: An Imaging-Pathology Comparison.

Neurocritical care·2026

Same author

Genome-wide identification and expression analysis of YTH domain-containing RNA-binding protein family in maize reveals their potential role under abiotic stresses.

Scientific reports·2026

Search research articles

Related Experiment Video

Updated: Jun 10, 2026

Antigenic Liposomes for Generation of Disease-specific Antibodies

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

Apolipoprotein-E genotypes and myasthenia gravis.

Hamid Suhail¹, Christhunesa C Soundararajan, Subbiah Vivekanandhan

¹Department of Neurology, All India Institute of Medical Sciences, New Delhi, India.

Neurology India

|July 21, 2010

Summary

This summary is machine-generated.

This study found no general link between apolipoprotein E (Apo-E) alleles and myasthenia gravis (MG). However, the Apo-E4 allele was associated with acetylcholine receptor antibody-positive MG, particularly in female patients.

More Related Videos

The Neuromuscular Junction: Measuring Synapse Size, Fragmentation and Changes in Synaptic Protein Density Using Confocal Fluorescence Microscopy

The Neuromuscular Junction: Measuring Synapse Size, Fragmentation and Changes in Synaptic Protein Density Using Confocal Fluorescence Microscopy

Published on: December 26, 2014

Related Experiment Videos

Last Updated: Jun 10, 2026

Antigenic Liposomes for Generation of Disease-specific Antibodies

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

The Neuromuscular Junction: Measuring Synapse Size, Fragmentation and Changes in Synaptic Protein Density Using Confocal Fluorescence Microscopy

The Neuromuscular Junction: Measuring Synapse Size, Fragmentation and Changes in Synaptic Protein Density Using Confocal Fluorescence Microscopy

Published on: December 26, 2014

Area of Science:

Neuroimmunology
Genetics
Biochemistry

Background:

Autoimmune myasthenia gravis (MG) is a neuromuscular junction disorder with potential genetic underpinnings.
Investigating genetic factors like apolipoprotein E (Apo-E) alleles may elucidate MG pathogenesis.

Purpose of the Study:

To examine the association between apolipoprotein E (Apo-E) alleles and myasthenia gravis (MG).
To determine if Apo-E genotypes correlate with anti-acetylcholine receptor (AChR) antibody status in MG patients.

Main Methods:

A case-control study involving 120 MG patients and 120 healthy controls.
Measurement of anti-AChR antibodies via radio receptor immunoassay.
Analysis of Apo-E genotypes.

Main Results:

No significant association was found between Apo-E allelic variants and MG overall.
A significant association was observed between the Apo-E4 allele and acetylcholine receptor antibody-positive (AChR-positive) MG patients (P = 0.007).
Among seropositive patients, the Apo-E4 allele showed a significant association with female gender (P = 0.023).

Conclusions:

The Apo-E4 allele may influence seropositive status in myasthenia gravis.
Apo-E4 appears to be a potential susceptibility factor for MG, especially in females.